In this issue of Clinics in Liver Disease, guest editor Mitchell L Shiffman brings considerable expertise to the topic of Challenging Issues in the Management of Chronic Hepatitis B Virus. - Provides in-depth, clinical reviews on the latest updates in Challenging Issues in the Management of Chronic Hepatitis B Virus, providing actionable insights for clinical practice. - Presents the latest information on this timely, focused topic under the leadership of experienced editors in the field; Authors synthesize and distill the latest research and practice guidelines to create these timely topic-based reviews.

Hepatitis B and C cause most cases of hepatitis in the United States and the world. The two diseases account for about a million deaths a year and 78 percent of world's hepatocellular carcinoma and more than half of all fatal cirrhosis. In 2013 viral hepatitis, of which hepatitis B virus (HBV) and hepatitis C virus (HCV) are the most common types, surpassed HIV and AIDS to become the seventh leading cause of death worldwide. The world now has the tools to prevent hepatitis B and cure hepatitis C. Perfect vaccination could eradicate HBV, but it would take two generations at least. In the meantime, there is no cure for the millions of people already infected. Conversely, there is no vaccine for HCV, but new direct-acting antivirals can cure 95 percent of chronic infections, though these drugs are unlikely to reach all chronically-infected people anytime soon. This report, the first of two, examines the feasibility of hepatitis B and C elimination in the United States and identifies critical success factors. The phase two report will outline a strategy for meeting the elimination goals discussed in this report.

In this issue of Clinics in Liver Disease, Guest Editor Paul Kwo brings his considerable expertise to the topic of Alcoholic Hepatitis. Top experts in the field cover key topics such as the Epidemiology of Alcoholic Hepatitis, Nutrition in Those with Alcoholic Hepatitis, Current therapies for alcoholic hepatitis, Selection Criteria for Liver Transplantation for Acute Alcoholic Hepatitis, and more. - Provides in-depth, clinical reviews on Alcoholic Hepatitis, providing actionable insights for clinical practice. - Presents the latest information on this timely, focused topic under the leadership of experienced editors in the field; Authors synthesize and distill the latest research and practice guidelines to create these timely topic-based reviews. - Contains 11 relevant, practice-oriented topics including Emerging Therapies for alcoholic hepatitis; Diagnosis of Alcoholic Hepatitis; Moderate Alcoholic Hepatitis; Current and Future Biomarkers in Alcoholic Hepatitis, and more.

In this issue, guest editors bring their considerable expertise to this important topic.Provides in-depth reviews on the latest updates in the field, providing actionable insights for clinical practice. Presents the latest information on this timely, focused topic under the leadership of experienced editors in the field. Authors synthesize and distill the latest research and practice guidelines to create these timely topic-based reviews.

In collaboration with Consulting Editor, Dr. Norman Gitlin, Guest Editors Drs. Andres Cardenas and Thomas Reiberger have created an up-to-date monograph on the complications of cirrhosis. They have secured top experts to contribute clinical review articles on the following topics: Non-invasive Detection of CSPH in cACLD; Prevention of First Decompensation in ACLD; Treatment of Acute Variceal Bleeding in 2020: When to Use TIPS; Prevention of Variceal Bleeding and Rebleeding by NSBB: A Tailored Approach; The Role of Hepatic Venous Pressure Gradient (HVPG); Measurement in the Management of Cirrhosis; Bacterial Infections in Cirrhosis as a Cause or Consequence of Decompensation; Nutrition in Chronic Liver Disease; Diagnosis and Management of Hepatic Encephalopathy; Discriminating Acute Decompensation from Acute-on-Chronic Liver; Management of Severe and Refractory Ascites; Monitoring Renal Function and Therapy of HRS patients with Cirrhosis; Coagulopathy in Cirrhosis; and Current Concepts of Cirrhotic Cardiomyopathy. Hepatologists will come away with the information they need to manage these patients.

With collaboration from Consulting Editor, Dr. Norman Gitlin Dr. Goldberg has assembled a state-of-the-art issue devoted to management of liver transplant patients. Expert authors have contributed current clinical reviews that covers the breadth of the pre- and post-surgical journey. Articles are specifically devoted to the following topics: Obesity management of liver transplant waitlist candidates and recipients; Expanding the limits of liver transplantation for hepatocellular carcinoma: Is there a limit; Frailty and sarcopenia in patients pre- and post-liver transplant; Achieving tolerance in liver transplantation: Where are we now and what does the future hold; Expanding role of donation after cardiac death donors; Optimizing selection of patients for simultaneous liver-kidney transplant; Keeping the patient with end-stage liver disease alive while awaiting transplant: Management of complications of portal hypertension; Expanding donor selection and recipient indications for living donor liver transplantation; The changing liver transplant recipient: From hepatitis C to NASH and alcohol; Cardiovascular risk stratification in liver transplant candidates; The role of machine perfusion in liver transplantation: Warm, Cold, or does it not matter; Paradigm shift in utilization of livers from hepatitis C-viremic donors into HCV-negative patients; Transplantation of elderly patients: Is there an upper age cutoff; Transplantation for acute alcoholic hepatitis: Controversies and early successes. Hepatologists will come away with the information they need to improve outcomes in liver transplant patients.

The global epidemic of hepatitis B and C is a serious public health problem. Hepatitis B and C are the major causes of chronic liver disease and liver cancer in the world. In the next 10 years, 150,000 people in the United States will die from liver disease or liver cancer associated with chronic hepatitis B virus (HBV) or hepatitis C virus (HCV) infections. Today, between 800,000 and 1.4 million people in the United States have chronic hepatitis B and between 2.7 and 3.9 million have chronic hepatitis C. People most at risk for hepatitis B and C often are the least likely to have access to medical services. Reducing the rates of illness and death associated with these diseases will require greater awareness and knowledge among health care workers, improved identification of at-risk people, and improved access to medical care. Hepatitis B is a vaccine-preventable disease. Although federal public health officials recommend that all newborns, children, and at-risk adults receive the vaccine, about 46,000 new acute cases of the HBV infection emerge each year, including 1,000 in infants who acquire the infection during birth from their HBV-positive mothers. Unfortunately, there is no vaccine for hepatitis C, which is transmitted by direct exposure to infectious blood. Hepatitis and Liver Cancer identifies missed opportunities related to the prevention and control of HBV and HCV infections. The book presents ways to reduce the numbers of new HBV and HCV infections and the morbidity and mortality related to chronic viral hepatitis. It identifies priorities for research, policy, and action geared toward federal, state, and local public health officials, stakeholder, and advocacy groups and professional organizations.